Abbott, Aventis Trandolapril deal

ABT said it will acquire from Aventis (AVE) global manufacturing rights and all remaining commercial rights except in Japan for cardiovascular compounds trandolapril and the trandolapril/verapamil combination. Under the deal, AVE will receive upfront and milestone payments of $300 million, plus royalties. ABT said the deal will not affect 2004 EPS and should be accretive in 2005. ...